No Data
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Altimmune, FDA Agree on Efficacy Measures for Phase 3 Trial of Pemvidutide
Express News | Altimmune Inc - Phase 3 Program to Enroll Approximately 5,000 Subjects
Express News | Altimmune Announces Successful Completion of End-of-Phase 2 Meeting With FDA for Pemvidutide in the Treatment of Obesity
Earnings Preview: Altimmune to Report Financial Results on November 12
$Altimmune(ALT.US)$ is scheduled to release its financial results on November 12 ET. Earnings PreviewAnalysts estimate $Altimmune(ALT.US)$ to post revenue of USD620.00 for 2024Q3, down 99.83% YoY;
No Data
No Data
